HealthDay News — For patients with type 1 diabetes (T1D) undergoing a first multivessel revascularization, percutaneous coronary intervention (PCI) is associated with increased risks of coronary heart disease mortality, myocardial infarction, and repeat revascularization, compared with coronary artery bypass grafting (CABG), according to a study published online August 26 in the Journal of the American College of Cardiology. The research was published to coincide with the European Society of Cardiology Congress 2017, held from Aug. 26 to 30 in Barcelona, Spain.
Thomas Nyström, MD, PhD, from the Karolinska Institutet in Stockholm, and colleagues conducted an observational cohort study involving patients with T1D who underwent a first multivessel revascularization from 1995 to 2013 (683 patients who underwent CABG and 1,863 who underwent PCI).
The researchers found that 53% of patients in the CABG group and 45% in the PCI group died during a mean follow-up of 10.6 years. Comparing PCI vs CABG, PCI was associated with similar risks of all-cause mortality (hazard ratio, 1.14; 95% confidence interval, 0.99 to 1.32), and with elevated risks of coronary heart disease mortality (hazard ratio, 1.45; 95% confidence interval, 1.21 to 1.74), myocardial infarction (hazard ratio, 1.47; 95% confidence interval, 1.23 to 1.78), and repeat revascularization (hazard ratio, 5.64; 95% confidence interval, 4.67 to 6.82). There were no differences noted in the risks for stroke or heart failure.
“CABG may be the preferred strategy in patients with T1D in need of multivessel revascularization,” the authors write.
One author disclosed financial ties to Actelion and Pfizer.